<DOC>
	<DOCNO>NCT02191241</DOCNO>
	<brief_summary>To describe plasma urinary pharmacokinetics quercetin glucuronide kaempferol glucuronide administration single peroral dose 1,800mg Red Vine Leaf Extract ( Antistax® ) . Additionally , trial evaluate safety tolerability dose healthy subject .</brief_summary>
	<brief_title>Pharmacokinetics Single Oral Dose 1,800 mg Red Vine Leaf Extract ( Antistax® )</brief_title>
	<detailed_description />
	<criteria>male female ( female : either nonchildbearing potential take adequate contraceptive measure ) caucasian age : 18 40 year old body mass index ( BMI ) : 1828 kg x m2 subject basis extensive pretrial investigation could consider healthy subject willing capable confirm write consent enrolment ample information provide female : positive pregnancy test upon recruitment subject relevant clinical abnormality ( base extensive medical history , physical examination , vital sign ) subject chronic relevant acute infection subject therapyrequiring allergy ( include drug allergy ) subject suspicion hypersensitivity investigational medication subject clinically relevant laboratory abnormality ( include positive result hepatitis HIV serology ) subject receive medication within 1 week prior trial start trial , except hormonal contraceptive ( female ) thyroid hormone replacement thyroidectomy subject take drug long halflife ( ≥ 24 hour ) within one month enrolment trial subject participate trial novel investigational medication within last 8 week start present trial subject participate trial register compound within last 4 week start present trial subject donate blood plasma within last 4 week start present trial subject smoke 15 cigarette per day subject willing able abstain smoke 12:00 hour profile day subject know suspected ( social ) drug dependent , incl . drink 60 g alcohol per day willing abstain alcohol active trial phase subject adhere diet ( i.e . vegetarian ) lifestyle ( include extreme physical activity competitive sport weight lift ) might interfere investigation subject know suspect comply trial directive and/or know suspected reliable trustworthy subject know suspect capable understanding evaluate information give part formal information policy ( informed consent ) , particular regard risk discomfort would agree expose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>